Review of Pulsed Reduced Dose Rate Re-irradiation for Recurrent Tumors

Image

On behalf of the Journal cancer clinical Trials, as Editor-in-Board, it is my distinct honour and privilege to inform you that, it’s been four years we have started the Journal, now we are celebrating the 4th Anniversary and we are privileged to welcome Analytical Society to our journal. Cancer Clinical Trials Data is electronically managed by databases. It keeps the patient information confidential. Research methodology, protocol preparation, quality and integrity of data are maintained. Clinical trial data is well organised for successful management of trial.

Cancer is a group of diseases results in abnormal cell growth with the ability to invade or spread to other parts of the body. Not all tumors are cancerous; benign tumors do not spread to other parts of the body. The symptoms of the disease includes new lump, abnormal bleeding, prolonged cough, unexplained weight loss, and a change in bowel movements. Cancer Clinical trials are research studies carried out on human volunteers to test the efficacy of a new drug or procedures. These studies are mainly conducted to prevent, detect or treat cancer

Review of Pulsed Reduced Dose Rate Re-irradiation for Recurrent Tumors:

Abstract:

Pulsed Reduced Dose Rate (PRDR) is an external beam re-irradiation technique that may be appropriate for recurrent tumors in patients who have previously undergone radiation treatment. PRDR is thought to effectively target dividing neoplastic cells that display Low-Dose Hyper-Radiosensitivity (LDHRS) while permitting sub-lethal damage repair in non-proliferating normal tissues. To date, only a few case reports and several retrospective studies have reported on efficacy after PRDR retreatment across several disease sites, including CNS, breast, and nasopharyngeal tumors. In this article, we review available publications of PRDR re-irradiation in patients. Taken together, this research demonstrates that PRDR offers a treatment option for large volume recurrent disease at previously irradiated sites. More research is needed to establish therapeutic benefit and late adverse effects for each disease site.

For full length article go through the link: https://www.omicsonline.org/open-access/review-of-pulsed-reduced-dose-rate-reirradiation-2577-0535-1000143.pdf

 

Manuscripts can be uploaded online at Editorial Tracking System (https://www.scholarscentral.org/submissions/cancer-clinical-trials.html) or forwarded to the Editorial Office   cancer@peerjournal.org

Media Contact:

Rebecca J
Assistant Editorial Manager
Journal of Cancer Clinical Trials
Whatsapp No:  +1-504-608-2390
Email:  cancer@eclinicalsci.com